Publications by authors named "Noritsugu Yamasaki"
Eur J Pharmacol
June 2004
Article Synopsis
- The study assessed the antidiabetic effects of a new compound, FK614, in comparison with existing medications like rosiglitazone and pioglitazone, using diabetic mice models.
- FK614 demonstrated comparable effectiveness in reducing blood sugar and significantly improved triglyceride levels, particularly in db/db mice, highlighting its strong therapeutic potential.
- While FK614 activated PPARgamma similar to thiazolidinedione drugs, it showed a lower maximum effect, and toxicity studies indicated it may have a safer profile than rosiglitazone, suggesting FK614 could be a promising candidate for type 2 diabetes treatment.
